Cited by 174Nanoparticle-Based Drug DeliveryNanoplatforms for cancer theranosticsRadiation Therapy and Dosimetry

Hybrid nanoparticles for combination therapy of cancer

Open access
He, Chunbai, Lu, Jianqin, Lin, Wenbin·2015·Journal of Controlled Release

Abstract

Nanoparticle anticancer drug delivery enhances therapeutic efficacies and reduces side effects by improving pharmacokinetics and biodistributions of the drug payloads in animal models. Despite promising preclinical efficacy results, monotherapy nanomedicines have failed to produce enhanced response rates over conventional chemotherapy in human clinical trials. The discrepancy between preclinical data and clinical outcomes is believed to result from the less pronounced enhanced permeability and retention (EPR) effect in and the heterogeneity of human tumors as well as the intrinsic/acquired drug resistance to monotherapy over the treatment course. To address these issues, recent efforts have been devoted to developing nanocarriers that can efficiently deliver multiple therapeutics with controlled release properties and increased tumor deposition. In ideal scenarios, the drug or therapeutic modality combinations have different mechanisms of action to afford synergistic effects. In this review, we summarize recent progress in designing hybrid nanoparticles for the co-delivery of combination therapies, including multiple chemotherapeutics, chemotherapeutics and biologics, chemotherapeutics and photodynamic therapy, and chemotherapeutics and radiotherapy. The in vitro and in vivo anticancer effects are also discussed.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jconrel.2015.09.029

Cites

106 of 106 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Synthetic tunability enables the creation of smart nanoparticles that can simultaneously serve several therapeutic or imaging goals by co-encapsulating various therapeutic compounds with various release curves.

    “For instance, synthetic tunability enables the creation of smart nanoparticles that can simultaneously serve several therapeutic or imaging goals by co-encapsulating various therapeutic compounds with various release curves.22,23”

    From Smart nanoparticles for cancer therapy (2023) · cites this paper as [23]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

2 of the 108 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

  1. [57]He C Lu K Liu D Lin W Nanoscale Metal–Organic Frameworks for the Co-Delivery of Cisplatin and Pooled siRNAs to Enhance Therapeutic Efficacy in Drug-Resistant Ovarian Cancer Cells J Am Chem Soc 136 2014 5181 5184 24669930 PMC4210117
  2. [88]He C Lu K Liu D Lin W Nanoscale Metal-Organic Frameworks for the Co-Delivery of Cisplatin and Pooled siRNAs to Enhance Therapeutic Efficacy in Drug-Resistant Ovarian Cancer Cells J Am Chem Soc 136 2014 5181 5184 24669930 PMC4210117

Cited by

Sorted by citations

Authors
He, C., Lu, J., & Lin, W.
Affiliations
University of Chicago (US)
Corresponding author
Lin, Wenbin
Venue
Journal of Controlled Release
Publisher
Elsevier BV
Published
2015-12
Volume
219
Pages
224-236
ISSN
0168-3659 (ISSN-L)
OpenAlex
W1770290865
Cited by
174
References
108
Citations by year
2026: 16 · 2025: 28 · 2024: 19 · 2023: 13 · 2022: 13 · 2021: 13 · 2020: 16 · 2019: 15 · 2018: 9 · 2017: 20 · 2016: 12
FWCI
4.95
Type
journal article
Language
en
Open access
Locations
  • Journal of Controlled Release (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • NIH (U01-CA151455)
  • University of Chicago Medicine Comprehensive Cancer Center (P30 CA014599)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Radiation Therapy and Dosimetry
Keywords
hybrid nanostructures, combination cancer therapy, co-delivery, nanocarriers, drug resistance, enhanced permeability and retention effect, tumor heterogeneity, photodynamic therapy, radiotherapy, chemotherapeutics, biologics, controlled release, synergistic drug delivery
MeSH terms
Animals, Antineoplastic Agents, Drug Combinations, Ferric Compounds, Gold, Humans, Neoplasms, Organometallic Compounds, Polymers, Drug Delivery Systems, Organosilicon Compounds, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review